Abelacimab
Based on 1 publication(s) in Google Scholar
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
For research use only. We do not sell to patients.
- Purity : 98.63%
- CAS No.: 2098724-83-3
- Molecular Weight:147.32 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
F11/Factor XI
In Vitro
In Vivo
Abelacimab (MAA868) (i.v., 0.6 mg/kg) exhibits good anticoagulant activity to prevent carotid artery occlusion in iron chloride induced thrombosis FXI-/- C57BL/6 mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Factor XI Protein (His Tag) can bind Abelacimab. The EC50 for this effect is 1.40 ng/mL.
Product Details
-
CAS No. 2098724-83-3
-
Accession P03951
-
Synonyms MAA868
-
Molecular Weight 147.32 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda2
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
98.63%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516. [Content Brief]
[2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)